Short answer
Charles River Laboratories (CRL) filed its Q2 2025 10-Q quarterly report on Aug 6, 2025 for the quarter ended Jun 28, 2025. Quarterly revenue was $1.0B (up 0.6% year over year) with net income of $52M.
Q2 2025 key financials · XBRL
- Revenue
- $1.0B
- +0.6% YoY · +4.9% QoQ
- Net income
- $52M
- −44.4% YoY · +105.4% QoQ
- Operating margin
- 9.7%
- EPS (diluted)
- $1.05
- −39.7% YoY · +110.0% QoQ
Source: XBRL data from the Charles River Laboratories (CRL) Q2 2025 10-Q on SEC EDGAR. USD.
Charles River Laboratories Q2 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New trade tariffs risk triggered by April 2025 U.S. and other countries’ tariff delays but key tariffs on Vietnam, Mauritius, China remain affecting costs and supply chain
- Material regulatory risk updated with April 2025 FDA plans to reduce animal testing using NAMs; potential adverse impact on services and revenues highlighted
- Most impactful compliance risk: potential fines and business denial from failure to comply with extensive animal research and trade oversight agencies’ regulations
- Operational risk tied to uncertainties in NIH funding post-February 2025 overhead payments reduction policy, potentially delaying client purchases and impacting revenue
- Financial risk tied to concentration in government R&D funding, subject to political budget changes and NIH grant uncertainties affecting RMS segment revenue
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Charles River Laboratories quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.